We provide a wide range of solid phase peptide synthesis for linear and branched chain peptides on small scale up to 70 AA, as well as development and manufacturing up to 40 AA. Aurigene Pharmaceutical Services uses automated peptide synthesizers (80-160 L) and small-scale equipment to produce research-grade material and the development of process designs. Multi-gram to multi-kilogram production for toxicology studies and clinical trials are typically performed by solid-phase synthesis and corresponding cleavage systems. Understanding the thermal sensitivity of the compounds, we use lyophilization (Capacity: 3 x 100 L) to isolate the final product.
With a capacity of up to 15 L, our microwave mediated peptide synthesizer (Liberty Pro) has become an established technology, which facilitates challenging couplings and drastically reduces the peptide synthesis time.
Synthesis of peptide APIs, NCEs and other services
Our integrated API and formulation services for peptides provide a holistic approach from early API and formulation development and can accelerate your timelines while offering technical and cost advantages.
As a CDMO, we are highly regulated by global agencies to ensure the safety and quality of our products. All our cGMP manufacturing facilities are regularly inspected by global regulatory authorities including the US FDA, MHRA or TGA.
Our regulatory team works closely with your CMC teams and has a track record of numerous DMF, IND, NDA and IMPD filings.
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.